Symptom Reduction and Suicide Risk Among Patients Treated With Placebo in Antipsychotic Clinical Trials: An Analysis of the Food and Drug Administration Database
The DOI matches its Crossref record.
Abstract
OBJECTIVE: The assumption that psychotic patients assigned to placebo in clinical trials of antipsychotics are exposed to substantial morbidity and mortality is not based on data about what actually happens to such patients. This study assesses symptoms and risks of suicide and suicide attempts in psychotic patients assigned to receive placebo in clinical trials. METHOD: The authors used the Food and Drug Administration database to assess suicides, suicide attempts, and psychotic symptom reduction in clinical trials of three new antipsychotics. RESULTS: Among 10,118 participating patients, 26 committed suicide and 51 attempted suicide. Rates of suicide and attempted suicide did not differ significantly between the placebo-treated and the drug-treated groups. Annual rates of suicide and attempted suicide based on patient exposure years were 1.8% and 3.3%, respectively, with placebo; 0.9% and 5.7% with an established antipsychotic; and 0.7% and 5.0% with a new antipsychotic. Symptom reduction was 16.6% with new antipsychotics (N=1,203), 17.3% with established antipsychotics (N=261), and 1.1% with placebo (N=462). CONCLUSIONS: These data may help inform discussions about the use of placebo in antipsychotic clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
“1%, a rate not appreciably different from that for use of atypical antipsychotic drugs in the study by Khan et al.(11) Given that the selection criteria for the InterSePT study population required evidence for a high risk of suicide, a higher rate of treatment-emergent suicidal behaviors was expected than was describe…”
BackgroundResultInfluentialCusack, K., Jonas, D. E., Forneris, C. A., Wines, C., Sonis, J., Middleton, J. C., Feltner, C., Brownley, K. A., Olmsted, K. R., Greenblatt, A., et al. (2016) · Clinical Psychology Review · doi:10.1016/j.cpr.2015.10.003 · Cited by 865
Alper, K., Schwartz, K. A., Kolts, R. L., & Khan, A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.023 · Cited by 522
Self-citationRanjekar, P. K., Hinge, A., Hegde, M. V., Ghate, M., Kale, A., Sitasawad, S., Wagh, U. V., Debsikdar, V. B., & Mahadik, S. P. (2003) · Psychiatry Research · doi:10.1016/s0165-1781(03)00220-8 · Cited by 395
Suicide risk in schizophrenia: learning from the past to change the future
Pompili, M., Amador, X. F., Girardi, P., Harkavy-Friedman, J., Harrow, M., Kaplan, K., Krausz, M., Lester, D., Meltzer, H. Y., Modestin, J., et al. (2007) · Annals of General Psychiatry · doi:10.1186/1744-859x-6-10 · Cited by 358
Metadata
- Authors
- Khan, A., Khan, S. R., Leventhal, R. M., & Brown, W. A.
- Venue
- American Journal of Psychiatry
- Published
- 2001-09-01
- Volume
- 158
- Issue
- 9
- Pages
- 1449-1454
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W1987417156
- Cited by
- 130
- References
- 0
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Symptom Reduction and Suicide Risk Among Patients Treated With Placebo in Antipsychotic Clinical Trials: An Analysis of the Food and Drug Administration Database. https://app.cochat.ai/papers/10.1176/appi.ajp.158.9.1449
- The paper
- Khan, A., Khan, S. R., Leventhal, R. M., & Brown, W. A. (2001). Symptom Reduction and Suicide Risk Among Patients Treated With Placebo in Antipsychotic Clinical Trials: An Analysis of the Food and Drug Administration Database. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.158.9.1449
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.